Dechra - HY-50 17 mg/ml, 3 ml EU

Dechra - HY-50 17 mg/ml, 3 ml EU
Nr. 42003EU
HY-50 is a sterile injectable solution of hyaluronate sodium indicated for horses with lameness associated with joint dysfunction.
Read more


HY-50 is a highly purified, sterile, pyrogen-free aqueous solution of hyaluronate sodium derived by a fermentation process using Streptococcus spp. and then purified to yield a product which is essentially free of protein and nucleic acids.

Hyaluronate is a naturally occurring substance present in connective tissue, skin, vitreous humour, synovial fluid and umbilical cord in all mammals. Hyaluronate is synthesized by synoviocytes and is responsible for the viscoelastic characteristic of synovial fluid. Synovial fluid hyaluronate functions as a lubricant of the intra-articular soft tissues, aids in providing nourishment and removing waste products from the avascular cartilage, and is an important constituent of the synovial membrane barrier. The surface of articular cartilage is coated by a thin amorphous layer of a protein-hyaluronate complex. Hyaluronate is also found in the superficial layers of the cartilage matrix where it exerts resistance to cartilage compression while retaining plasticity. Hyaluronate has biochemical activities which are distinct from its physical properties. It is a potent inhibitor of cell migration, a direct inhibitor of leucocyte activity, and it prevents the formation of excess fibrous tissue.

HY-50 is indicated for the intra-articular or intravenous treatment of carpal and fetlock joint dysfunction in horses due to acute or chronic non-infectious synovitis associated with equine osteoarthritis.

Additional Information

Additional Information

SKU 42003EU
Tax Class 9%
Brand Dechra
Route of Administration I.A., I.V.
Active Ingredient Hyaluronate sodium
Withdrawal period Not to be used in horses that are to be slaughtered for use in food.
Target Species Equine
Registrationnumber Cascade
Units per outerbox 1
Ingredients Each mL contains: hyaluronate sodium 17 mg; sodium chloride 7.57 mg; sodium phosphate dibasic 3.78 mg; sodium phosphate monobasic 0.45 mg; and water for injection q.s.

Additional Information

Instructions for use

Intravenous route: The recommended dose of HY-50 is 51 mg hyaluronate sodium (contents of one syringe) once a week for three consecutive weeks.

Intra-articular route: The recommended dose of HY-50 is 51 mg hyaluronate sodium (contents of one syringe) in small or medium sized joints (i.e. carpus, fetlock) by intra-articular injection. More than one joint may be treated at the same time.

Treatment may be repeated after one or more weeks if necessary, but not to exceed four consecutive weekly injections in the same joint.